ESR1 and osteoporosis: Current pharmacological treatments for osteoporosis, including bisphosphonates, selective estrogen receptor modulators, and monoclonal antibodies, effectively reduce fracture risk but are associated with limitations such as adverse effects, high cost, and reduced long-term adherence [11,12].